PMID- 22642898
OWN - NLM
STAT- MEDLINE
DCOM- 20121025
LR  - 20220607
IS  - 1943-7811 (Electronic)
IS  - 1525-1578 (Linking)
VI  - 14
IP  - 4
DP  - 2012 Jul
TI  - Improved method of detecting the ERG gene rearrangement in prostate cancer using 
      combined dual-color chromogenic and silver in situ hybridization.
PG  - 322-7
LID - 10.1016/j.jmoldx.2012.01.017 [doi]
AB  - The recently detected TMPRSS2-ERG fusion gene was revealed as a recurrent and 
      prevalent prostate cancer (PCa)-specific event, potentially qualifying it for 
      clinical use. To detect this alteration, fluorescence in situ hybridization 
      (FISH) is the method of choice. However, FISH has some disadvantages for 
      widespread adoption in clinical practice. Subsequently, chromogenic in situ 
      hybridization, which uses organic chromogens, and enzymatic metallography silver 
      in situ hybridization have emerged as promising bright-field alternatives. 
      Compared with chromogenic in situ hybridization, silver in situ hybridization 
      signals are very distinct and superior with regard to signal clarity and 
      resolution, but the method excludes multicolor protocols. Based on the ERG 
      break-apart FISH assay, we established a dual-color ERG break-apart assay using 
      combined chromogenic in situ hybridization and silver in situ hybridization 
      (CS-ISH) and compared these results with those obtained by FISH. We assessed 178 
      PCa and 10 benign specimens for their ERG rearrangement status by applying 
      dual-color FISH and CS-ISH ERG break-apart assays to consecutive sections. We 
      observed a highly significant concordance (97.7%) between FISH- and CS-ISH-based 
      results (Pearson's correlation coefficient = 0.955, P < 0.001). Our findings 
      demonstrate that the ERG rearrangement status can reliably be assessed by CS-ISH. 
      Further, the CS-ISH technique combines the accuracy and precision of FISH with 
      the ease of bright-field microscopy. This tool allows a much broader spectrum of 
      applications in which to study the biological role and clinical use of ERG 
      rearrangements in PCa.
CI  - Copyright (c) 2012 American Society for Investigative Pathology and the Association 
      for Molecular Pathology. Published by Elsevier Inc. All rights reserved.
FAU - Braun, Martin
AU  - Braun M
AD  - Institute of Pathology, University Hospital of Bonn, Sigmund-Freud-Strasse 25, 
      Bonn, Germany.
FAU - Stomper, Julia
AU  - Stomper J
FAU - Boehm, Diana
AU  - Boehm D
FAU - Vogel, Wenzel
AU  - Vogel W
FAU - Scheble, Veit J
AU  - Scheble VJ
FAU - Wernert, Nicolas
AU  - Wernert N
FAU - Adler, David
AU  - Adler D
FAU - Fend, Falko
AU  - Fend F
FAU - Kristiansen, Glen
AU  - Kristiansen G
FAU - Perner, Sven
AU  - Perner S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120527
PL  - United States
TA  - J Mol Diagn
JT  - The Journal of molecular diagnostics : JMD
JID - 100893612
RN  - 0 (ERG protein, human)
RN  - 0 (Trans-Activators)
RN  - 0 (Transcriptional Regulator ERG)
SB  - IM
MH  - Gene Rearrangement/*genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Male
MH  - Prostatic Neoplasms/*genetics
MH  - Trans-Activators/*genetics
MH  - Transcriptional Regulator ERG
EDAT- 2012/05/31 06:00
MHDA- 2012/10/26 06:00
CRDT- 2012/05/31 06:00
PHST- 2011/10/16 00:00 [received]
PHST- 2012/01/26 00:00 [revised]
PHST- 2012/01/31 00:00 [accepted]
PHST- 2012/05/31 06:00 [entrez]
PHST- 2012/05/31 06:00 [pubmed]
PHST- 2012/10/26 06:00 [medline]
AID - S1525-1578(12)00100-6 [pii]
AID - 10.1016/j.jmoldx.2012.01.017 [doi]
PST - ppublish
SO  - J Mol Diagn. 2012 Jul;14(4):322-7. doi: 10.1016/j.jmoldx.2012.01.017. Epub 2012 
      May 27.